Niraparib 100 mg (Niraparib) Capsules

Niranib 100 mg contains Niraparib, an oral Poly(ADP-Ribose) Polymerase (PARP) inhibitor used in oncology. It is prescribed as maintenance therapy for selected adult patients with certain ovarian, fallopian tube, or primary peritoneal cancers, depending on the patient's previous treatment, disease status, and eligibility determined by an oncologist.

Niraparib works by inhibiting PARP enzymes, particularly PARP-1 and PARP-2, which are involved in repairing damaged DNA. By interfering with these DNA repair mechanisms, Niraparib can increase the accumulation of DNA damage inside susceptible cancer cells. Tumor cells that already have deficiencies in other DNA-repair pathways may be particularly vulnerable to this effect.

Therapeutic Effects

• Supports maintenance treatment in eligible patients with certain ovarian cancers.
• May be used in selected fallopian tube cancer cases.
• May be prescribed for certain primary peritoneal cancers.
• Helps inhibit PARP-mediated DNA repair in cancer cells.
• May help delay disease progression in appropriate patients receiving maintenance therapy.
• Can be considered following a response or stable disease after platinum-based chemotherapy, depending on the approved indication and clinical circumstances.
• Treatment selection may depend on factors such as previous chemotherapy, biomarker status, treatment history, and individual patient characteristics.

Important: Niraparib is a prescription oncology medicine. It is not intended to replace chemotherapy or other cancer treatment unless specifically prescribed as part of an individualized treatment plan.

Active Ingredient

Niraparib — 100 mg

Niranib 100 mg capsules contain 100 mg of Niraparib as the active pharmaceutical ingredient. Niraparib belongs to the PARP inhibitor class of targeted anticancer medicines.

Pharmacological Role

Niraparib targets Poly(ADP-Ribose) Polymerase (PARP) enzymes, which participate in the repair of single-strand DNA damage. Blocking these enzymes can interfere with DNA repair and increase DNA damage within susceptible tumor cells.

The therapeutic activity of Niraparib is associated with its ability to inhibit PARP-mediated DNA repair and, at the cellular level, may promote accumulation of DNA damage and cancer-cell death.

Excipients

The inactive ingredients, capsule shell components, and other formulation excipients may vary according to the specific manufacturer and product formulation. For exact inactive ingredients, patients should check the official product packaging or package insert supplied with their medicine.

Niranib 100 mg should be taken exactly according to the prescription provided by the treating oncologist. The appropriate dose can vary according to the patient's clinical condition, previous treatment, laboratory results, tolerability, and the specific indication.

Standard Adult Dosing

For certain approved maintenance indications, the recommended Niraparib dose may be 200 mg or 300 mg once daily, depending on individual patient factors such as baseline body weight and platelet count. Therefore, 100 mg capsules may be used as part of the prescribed daily dose rather than necessarily representing the complete daily dose.

The exact dose must be determined by the prescribing oncology specialist.

How to Take Niraparib

• Take the capsules orally with water.
• Swallow the capsules whole; do not crush, chew, or open them unless specifically instructed by a healthcare professional.
• Niraparib may generally be taken with or without food.
• Try to take the medicine at approximately the same time each day.
• Follow the prescribed dose and schedule consistently.
• Do not change the dose or stop treatment without discussing it with your oncologist.
• Your doctor may adjust the dose or temporarily interrupt treatment if significant adverse effects or laboratory abnormalities occur.

Missed Dose

If a dose is missed or vomiting occurs after taking Niraparib, do not take an additional dose to compensate. The next dose should generally be taken at the regularly scheduled time according to the prescribing instructions.

Monitoring During Treatment

Regular medical monitoring is important during Niraparib therapy. Your healthcare professional may check:

• Complete blood count (CBC)
• Platelet count
• Hemoglobin levels
• White blood cell counts
• Blood pressure
• Liver function when clinically appropriate
• Kidney function when clinically appropriate
• Symptoms suggesting bleeding, infection, or other serious adverse reactions

Important Administration Advice

Niraparib treatment requires specialist supervision because it can affect blood-cell counts and may cause clinically important adverse reactions. Patients should attend scheduled follow-up appointments and laboratory tests throughout treatment.

Do not use someone else's Niraparib prescription, and do not alter the prescribed dose based solely on information found online. The appropriate treatment schedule should always be determined by a qualified oncology professional.